Clinical Omics – News and Features

Clinical trials produce a massive amount of medically relevant and highly sensitive data. Leveraging such data could make a difference to efforts to create more personalized, effective medicines. We talked to Medidata’s Sheila Diamond to find out more.

Researchers at the National Institutes of Health and the University of Wisconsin have demonstrated that using artificial intelligence to analyze CT scans can produce more accurate risk assessment for major cardiovascular events than current, standard methods such as the Framingham risk score (FRS) and body-mass index (BMI).

Technology Networks recently spoke with Stephen Williams, CMO at biotechnology company SomaLogic, to learn more about research progress in the proteomics space and the technology that has enabled it.

Researchers from the University of Maryland School of Medicine’s (UMSOM) Institute for Genome Sciences (IGS) have created VIRGO (human vaginal non-redundant gene catalog): the first genomic catalog of the vaginal microbiome.

In a new study scientists have harnessed advances in proteomics to extensively profile the secretions of senescent cells which are implicated in aging. Their analyses are collated in a database that is now available for researchers in the field.

Many clinical trials fail due to lack of efficacy. But while some of this may be due to poor target selection during the drug discovery process, it’s becoming increasingly clear that only certain patients respond to treatments. So how exactly does precision medicine increase the likelihood of success in clinical trials?

We recently spoke to Luca Quagliata, Ph.D., Global Head of Medical Affairs for Clinical NGS and Oncology at Thermo Fisher Scientific, to discuss some of the barriers preventing full adoption of NGS-based genomic testing in hospitals, and learn more about a solution that can help to address these.

In this article, Gary Kruppa, VP of Proteomics at Bruker Daltonics, explores how proteomic methods can help achieve the ultimate goal of preventing and improving the treatment of disease.

A new study has shown the power of genetic testing to pick out the best drugs for children with cancer to extend and improve their lives – signalling a new era of precision medicine for young patients.

Recent developments in MS technology have enabled a fourth dimension of analysis: ion mobility separation. The term "4D proteomics" has been created to describe analysis that incorporates all four dimensions. We interviewed two researchers at the forefront of the proteomics field to learn more about how 4D proteomics approaches are enhancing their research.